Lamrani et al. [38] found that the anti-cancer drug OM-174, a toll-like receptor (TLR) 4 agonist, induces iNOS expression in murine models of breast cancer, and the inhibition of iNOS expression was found to hinder the antitumor activity of the drug, supporting the role of .NO in TLR-mediated tumor suppression. Here, NOS2 is linked to breast carcinoma.